<DOC>
	<DOCNO>NCT02235961</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . The aim trial investigate safety , tolerability pharmacokinetics ( exposure trial drug body ) single dose NNC9204-0530 alone combination liraglutide overweight obese otherwise healthy male subject .</brief_summary>
	<brief_title>Investigate Safety , Tolerability Pharmacokinetics Single Doses NNC9204-0530 Alone Combination With Liraglutide Overweight Obese But Otherwise Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male , age ( inclusive ) 18 55 year time sign inform consent Overweight obese otherwise healthy male subject ; BMI equal 27.0 35.0 kg/m^2 Thyroid stimulate hormone value outside 0.46.0 mIU/l HbA1c ( glycated hemoglobin ) equal 6.5 % Any clinically relevant ECG ( electrocardiogram ) finding ( e.g . 2nd 3rd degree AVblock ) , particular subject repeat demonstration QTcF ( QT interval correct Fridericia formula ) interval 430 m A history additional risk factor Torsades de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) The use concomitant medication prolong QT/QTc interval Obesity cause endocrinology disorder ( e.g . Cushing 's Syndrome ) Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2 Calcitonin 50 ng/L History pancreatitis ( acute chronic )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>